Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly

Zyprexa, Gemzar patent losses impact results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly

4Q Revenues: $6.0 billion (-2%)

4Q Earnings: $858.2 million (-27%)

FY Revenues: $24 billion (+5%)

FY Earnings: $4.3 billion (-14%)

Comments: U.S. revenue was down 4% to $3.3 billion due to the loss of patent exclusivity for Zyprexa and Gemzar. Revenue outside the U.S. remained flat at $2.8 billion due to increased volume and the positive impact of foreign exchange rates, offset by lower prices. For the year revenue in the U.S. was $13.0 billion (+1%). Revenue outside the U.S. increased 11% to $11.3 billion due to increased demand and the positive impact of foreign exchange rates, partially offset by lower prices. Zyprexa sales were $749.6 million in the quarter, down 44%, and $4.6 billion for the year (-8%). Cymbalta sales were $1.2 billion in the quarter (+20%), and $4.2 billion for the year (+20%). Alimta sales were $638.1 million in the quarter (+12%), and $2.5 billion for the year (+11%). Humalog sales increased 21% in the quarter to $662.0 million, and 15% for the year to $2.4 billion. Cialis sales in the quarter were up 6% to $494.2 million and up 10% for the year to $1.9 billion. Gemzar sales were $92.6 million, down 62% in the quarter, and $452.1 million for the year, down 61%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters